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Abstract
Live-attenuated oral rotavirus (RV) vaccines have lower efficacy in low income countries,
and additionally are associated with a rare but severe adverse event, intussusception. We
have been pursuing the development of an inactivated rotavirus vaccine (IRV) using the
human rotavirus strain CDC-9 (G1P[8]) through parenteral immunization and previously
demonstrated dose sparing and enhanced immunogenicity of intradermal (ID) unadju-
vanted IRV using a coated microneedle patch in comparison with intramuscular (IM) admin-
istration in mice. The aim of this study was to evaluate the immune response and protection
against RV infection and diarrhea conferred by the administration of the ID unadjuvanted
IRV using the microneedle device MicronJet600® in neonatal gnotobiotic (Gn) piglets chal-
lenged with virulent Wa G1P[8] human RV. Three doses of 5 μg IRV when administered
intradermally and 5 μg IRV formulated with aluminum hydroxide [Al(OH)3] when adminis-
tered intramuscularly induced comparable rotavirus-specific antibody titers of IgA, IgG, IgG
avidity index and neutralizing activity in sera of neonatal piglets. Both IRV vaccination regi-
mens protected against RV antigen shedding in stools, and reduced the cumulative diar-
rhea scores in the piglets. This study demonstrated that the ID and IM administrations of
IRV are immunogenic and protective against RV-induced diarrhea in neonatal piglets. Our
findings highlight the potential value of an adjuvant sparing effect of the IRV ID delivery
route.
Introduction
Rotavirus (RV) infection causes severe dehydrating diarrhea in young children under 5 years
of age worldwide. In 2011 the annual estimated number of RV disease-associateddeath in the
<5 year old was 192,700 (133,100–284,400) and the majority of the fatalities occur in low
income countries of Africa and Asia where healthcare is not readily available or accessible [1].
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Two live oral vaccines, Rotarix and RotaTeq, have been shown to be generally safe and effica-
cious in developed and middle-income countries, and have been licensed for use in more than
100 countries, including the introduction into routine national immunization programs in 81
countries [2]. However, these vaccines have been shown to be less efficacious in many low-
income countries where an effective vaccine is neededmost due to highmorbidity and mortal-
ity [3–7]. The mechanisms for the gradient efficacies among children in different countries are
likely to be multifactorial, including in part the frailty of health care systems. Over the last sev-
eral years, various intervention studies, such as transient withholding of breastfeeding at the
time of immunization, delayed administration or addition of a third or more dose of vaccine,
have been conducted, but none to date have shown real improvement in the performance of
the vaccines [8–11]. The two vaccines have also been shown to be associated with rare but
severe intussusception in infants who received vaccine [12]. In addition, when these vaccine
virus strains and wild type human rotaviruses are present in the gut, they can reassort to pro-
duce new strains, including virulent double bovine-human rotavirus reassortants [13–16].
To address the problems associated with live oral rotavirus vaccines, parenteral immuniza-
tion with inactivated rotavirus vaccine (IRV) is an attractive approach for protection of chil-
dren against RV disease. Early studies provided the proof of principle of establishing
protection by a live or inactivated animal RV, or virus-like particles via intramuscular (IM)
administration [17–19]. After that we developed a candidate human RV vaccine CDC-9 (G1P
[8]) and demonstrated that this thermally inactivated CDC-9 formulated with Al(OH)3 adju-
vant and administered by IM injectionwas highly immunogenic in mice and guinea pigs and
conferred protection against homologous rotavirus challenge in gnotobiotic (Gn) piglets [20–
22]. Thus, a safer and potentially more widely effective IRV could be an alternative to the pre-
vention of rotavirus disease. However, the cost to manufacture an IRV for parenteral vaccina-
tion may be higher than that of producing live oral vaccines due to extra processes for
purification and inactivation.
One way to reduce the cost of the IRV is to deliver a fraction of the IM dose via intradermal
(ID) vaccination using novel innovative microneedle devices. The skin is rich in antigen pre-
senting cells (Langerhans cells, dermal dendritic cells, macrophages) and ID vaccination has
been shown to mount potent immune responses. Smallpox, tuberculosis and rabies vaccines
administered via ID route were highly effective in the prevention of these bacterial and viral
diseases [23–25]. Recent studies have demonstrated that inactivated polio vaccine (IPV) given
at a fractional dose versus full IM dose by ID route using devices such as needle-free jet injector
and hollow microneedles, induced seroconversions comparable to that of a full IM-dose IPV
[26]. Similarly, inactivated influenza vaccine, Fluzone, when administered using an ID device
at 60% of its IM vaccine dose, has shown equivalent protective efficacy against seasonal influ-
enza [27, 28]. MicronJet6001, a device registered by the US FDA, has been successfully tested
to deliver IPV, influenza, live attenuated zoster and other vaccines in clinical trials [26, 29–31].
In addition, significant dose sparing, using 20% of the dose, was achieved with various influ-
enza vaccines with the MicronJet6001 device [28, 29]. Furthermore, we recently demonstrated
apparent dose sparing and enhanced immunogenicity of the IRV without adjuvant when
administered transcutaneously using a coated metal microneedle patch compared to IM
administered IRV in mice [32].
The physiology and immune responses of Gn pigs mimic those of humans. Gn piglets also
show clinical signs of diarrhea and virus shedding post-HRV challenge similar to infants.
Moreover being outbred, pigs exhibit heterogeneity in immune responses similar to humans.
Thus, neonatal Gn piglets are a relevant animal model to investigate IRV [33–35]. In this
report, we assessed the immune responses of IRV administered by two different ways: ID using
a hollow microneedle injection deviceMicronJet6001 without adjuvant and IM with Al(OH)3
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The study protocol was approved by Institutional Animal Care and Use Committee (IACUC)
of the Ohio State University (Protocol Number: 2010A00000088) (S1 File). All the piglets were
maintained, samples collected, and then euthanized, and all efforts were made to minimize the
suffering of animals. The IACUC protocol describes early removal criteria (ERC) and humane
euthanasia methods. The ERC include euthanasia of animals if they developed severe diarrhea
or were non-responsive to treatment. Other criteria used to determine the end of study include
depression, anorexia, lethargy, lack of weight gain by visual appearance, abnormal behavior,
and dehydration. However, no animal developed such symptoms or became severely ill during
this experiment. No animals died prior to the experiment termination. Prior to euthanasia by
electrocution the pigs were anesthetized using TKZ combo (Telazol 100mg/ml, Ketamine
100mg/ml, Xylazine 100mg/ml). Otherwise the experiment involved no suffering to the ani-
mals and no modifications to housing/feeding/handlingprocedures (described in the protocol)
were required. Piglets were euthanized at the study termination.
Virus inocula
The intestinal contents of virulent human RV group A strainWa (VirWa) G1P[8] infectedGn
pigs were diluted in minimal essential medium (MEM; Invitrogen, Carlsbad, USA) and used
for challenge at a dose of 5x105 fluorescent-forming units (FFU). The 50% infectious dose
(ID50) of VirWa HRV in pigs was determined as approximately 1 FFU [36]
Vaccine preparation
CDC-9, a human G1P[8] rotavirus strain, was cultivated in Vero cells using Iscove’s Modified
Dulbecco’s Medium (IMDM; Invitrogen, Grand Island, NY) [37]. Triple-layered particles
(TLPs) were purified from culture supernatants by CsCl gradient equilibriumultracentrifuga-
tion, suspended in Hanks balanced salt solution (HBSS) containing 10% sorbitol, and inacti-
vated by incubation at 58°C for 4 hours [20]. Inactivation of CDC-9was confirmed by the lack
of virus growth in three sequential passages in Vero cells, which was measured with a commer-
cial immunoassay (Premium1 Rotaclone1 Kit; Meridian Diagnostics, Cincinnati, OH). Each
dose of ID vaccine contained 5 μg of IRV antigen in 0.2 ml. For IM vaccine, each dose con-
tained 5 μg of IRV antigen formulated with 600 μg of Al(OH)3 in 1.0 ml; 89% of the IRV anti-
gen was adsorbed to Al(OH)3 gel.
The MicronJet6001 device used for ID injectionwas manufactured by NanoPass Technolo-
gies [30, 31]. It is a single-use,microneedle based device, for ID delivery of vaccines and other
molecules into the skin. The device consists of 3 microneedles, each 0.6 mm in length, on a
hub, that can be mounted on any standard syringe. This device has the shortest needles ever
registered with the FDA.
Gnotobiotic pigs and experimental design
Gn piglets were derived by hysterectomy from the sows bred at the OSU swine herd. The pigs
were maintained in plastic flexible positive pressure isolator units supplied with filtered air and
received a UHT bovinemilk diet (Parmalat) twice a day as described in the protocol. The lights
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stayed on from 7AM-7PM and were regulated by automatic turn on/off. For vaccination,
eleven 3-day old Gn piglets from one litter were randomly divided into three groups; 3 received
2 x 100 μl of HBSS with 10% sorbitol by ID device as placebo control and 4 each received 2 x
100 μl of IRV by ID device or 2 x 500 μl of IRV adsorbed to Al(OH)3 gel by IM injection. ID
administrations were given at two sites on the abdomen with rich draining lymph nodes. The
skin was not shaved prior to the application. IM vaccine was administered in the ham area of
each hind leg. Three doses of vaccine or placebo were inoculated on post-vaccination days 0,
10 and 21.
Pig virus challenge, clinical observations and sample collection
On post-vaccination day 28, all 11 piglets were orally inoculatedwith the homologous human
RV VirWa, one of the most prevalent RV strains worldwide at a dose of 5x105 ID50. AfterWa
RV challenge, the animals were observeddaily for diarrhea and other clinical signs from 0 to
10 post inoculation days (PID). To estimate the severity of diarrhea, fecal consistency was
scored by qualified technicians as follows: 0 = solid; 1 = pasty; 2 = semi-liquid (moderate diar-
rhea); 3 = liquid (severe diarrhea). A score of 2 is considered diarrhea. Before and afterWa
HRV challenge, rectal swabs were collected daily to assess RV antigen shedding.Whole blood
samples were collected by jugular venipuncture in BD Li-Heparin vacutainers immediately
before each inoculation and on days 3, 5, 10 and 14 after the challenge and processed for
plasma according to the manufacturer’s instructions.
Porcine IgG, IgA ELISA
Rotavirus-specific IgG or IgA in sera of piglets was measured by using a modified enzyme
immunoassay (EIA) [20]. Briefly, 96-well plates (Immulon 2; NalgeNunc, Rochester, NY) were
coated with diluted rabbit hyperimmune serum to human rotavirusWa at 4°C overnight. After
washing, the plates were incubated at 37°C first with 5% skimmilk in PBS (blotto), and then
with supernatants of Wa rotavirus-infectedMA104 cell cultures (~106 FFU/ml) (36), followed
by the addition of serially diluted porcine sera. Plates were further incubated sequentially with
biotinylated anti-swine IgG (KPL, Gaithersburg, Maryland) or biotinylated goat anti-porcine
IgA (Bethyl Labs, Montgomery, TX), followed by addition of ExtrAvidin1−peroxidase (Sigma-
Aldrich, St. Louis,MO). The color of reactions was developedwith substrate tetramethyl benzi-
dine (TMB; Sigma-Aldrich) and stopped with 1N HCl. The optical density (OD) at 450 nm
was measured with an EIA reader (MRXRevelation, Dynex Technologies, Chantilly, VA).
Antibody titer in a serum specimenwas defined as the reciprocal of the highest dilution that
gave a mean OD greater than the cutoff value [3 standard deviations above the mean OD of the
blotto wells-(blank wells with no serum)].
Porcine IgG avidity assay
Rotavirus IgG avidity assay was performed by modifying the protocol of RV IgG EIA with the
denaturant agent diethylamine (DEA) [38]. One dilution series started at 1:200 and was washed
6 times with 0.05% Tween 20-PBS, the other dilution series started at 1:20 and was washed 3
times for 5 min with 60 mMDEA in 0.05% Tween 20-PBS (pH 11.0) and 3 times with 0.05%
Tween 20-PBS. End titer avidity index percentages (etAI%) were obtained using the formula
etAI% = (end-titer DEA curve / end-titer wash buffer curve) X 100 [38].
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Virus neutralization assays
Neutralizing activity in porcine sera was measured against homotypic and heterotypic human
rotavirus strains Wa (G1P[8]), WI61 (G9P[8]) and MW333 (G8P[4]), with a modifiedmicro-
neutralization assay [20]. Each strain was individually optimized to use 5,000 FFU for Wa; 600
FFU for WI61 and MW333. Neutralizing titer was defined as the reciprocal of the highest dilu-
tion that gave a greater than 70% reduction in the absorbance value compared to that in virus-
only control wells.
Porcine cytokines
Cytokines in porcine sera were measured with Swine CytokineMagnetic 7-Plex Panel kit (Life
technologies,Grand Island, NY) using Bio-Plex 200 (Bio-Rad,Hercules, CA) according to manu-
facturer’s instructions.Data collection and analysis were done using Bio-PlexManager 5.0.
RV antigen detection
Human RV shedding was detected in rectal swabs using Premier Rotaclone1 according to
manufacturer’s instructions.
Statistical analysis
Fisher’s exact test was used to compare proportions of animals with diarrhea and RV antigen
shedding among groups. The Kruskall-Wallis rank sum test (non-parametric) was used to
compare days of onset and duration of diarrhea and RV antigen shedding, cumulative diarrhea
scores and cumulative ODs of RV antigen shedding (area under the curve, AUC) among
groups that were recorded. Negative samples were assigned an arbitrary Ab titer of 1 for the
calculation of geometricmean titers (GMTs). Neutralizing and RV Ab titers were log10-trans-
formed prior to statistical analysis. Differences in Ab and neutralization Ab titers among
groups were evaluated by comparison of means using a 2-tailed t-test at different time-points
post virus inoculation. Statistical significancewas assessed at p< 0.05 for all comparisons. Sta-
tistical analyses were conducted using IBM1 SPSS1 Statistics Version 21.
Results
We assessed the safety of IRV in piglets by daily observation following each vaccination. No
local reactogenicity at injection sites and no fever or other systemic adverse events were found
in all placebo or IRV-vaccinated piglets.
ID and IM-administered IRV induced potent IgA, IgG, IgG avidity and
neutralizing antibody responses in piglets
We examined and demonstrated a dose-dependent rotavirus-specific IgA and IgG response to
IRV without Al(OH)3 administered with an ID device or IRV formulated with Al(OH)3
administered by IM injection (Fig 1). Piglets developed low titers of IgA and no detectable IgG
(< 100 titer) in sera by day 10 following first ID or IM vaccination. IM administration induced
19- and 20-fold higher geometricmean titers of IgA (p = 0.047) and IgG (p = 0.002) compared
with ID vaccination by post-vaccination day 21 after the second dose. After three doses, ID and
IM vaccines induced strong and comparable IgA (p = 0.252) and IgG (p = 0.031) titers at post-
vaccination day 28. By contrast, piglets in control group had no detectable IgA and IgG titers
in sera throughout the post-vaccination period of 28 days. To examine whether ID and IM vac-
cinations induced similar kinetics and accumulated strength of IgG interactions with the multi-
ple antigenic epitopes in rotavirus, we measured sera for rotavirus-specific IgG avidity index
Skin Vaccination against Rotavirus Using Microneedles
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Fig 1. Rotavirus-specific serum IgA and IgG antibody titers in control, ID or IM IRV-vaccinated piglets.
Each serum specimen was tested at an initial dilution of 1:10 for IgA (A) and 1:100 for IgG (B). If IgA or IgG activity
was not detected at initial dilution, a value of 1 for IgA and 10 for IgG was used for calculation and graphic
illustration. Data are presented as geometric mean titer (GMT) + one standard error (error bar). Filled, checker
board and open bars represent control, ID and IM groups, respectively. Significant differences are indicated.
doi:10.1371/journal.pone.0166038.g001
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(Fig 2). Piglets had no detectable levels of IgG avidity index in pre-bleed sera and sera 10 days
post dose 1. IgG avidity index was seen at comparable levels in sera of ID and IM IRV-vacci-
nated piglets 11 days post dose 2 (21 days post-vaccination) (p = 0.317) and increased to a
mean value of 31% and 35% seven days post dose 3 (28 days post-vaccination) (p = 0.502),
respectively. IgG avidity index continued to increase to more than 70% in both ID and IM vac-
cinated animals 14 days after the oral challenge (p = 0.693). None of the piglets in control
group had detectable IgG avidity index in sera throughout the study period until 14 days fol-
lowing the oral challenge.
We also measured sera for neutralizing activity against homotypic and heterotypic human
rotavirus strains (Fig 3). ID- and IM-administered IRV induced neutralizing antibody
responses to the homotypic Wa strain; strong comparable titers were seen after two inocula-
tions of ID and IM vaccinations (p = 0.207) and titers were further enhanced after three inocu-
lations (p = 0.182). In addition, ID- and IM-administered IRV induced lower but number of
inoculation-dependentneutralizing antibody responses to the partially heterotypic strainWI61
(G9P[8]) and the completely heterotypic strain MW333 (G8P[4]); comparable titers were seen
after three IM injections and ID administrations (WI61: p = 0.391; MW333: p = 0.537). In con-
trast, piglets in control group had little or no detectable neutralizing antibody against homoty-
pic and heterotypic strains throughout 28-day post vaccination. Oral challenge with a virulent
Wa strain further boosted neutralizing antibody responses, as reflected by GMT toWa by 16
folds (p = 0.001) and toWI61 andMW333 by 5–13 folds (p = 0.043, and p = 0.005 respectively)
in IM vaccinated animals at post challenge day 14. Similarly, the oral challenge also boosted
neutralizing antibody GMT toWa by 6.7 fold (p = 0.010) and to MW333 andWI61 by 4–7
fold (p = 0.045, and p = 0.100 respectively) in ID vaccinated piglets at post challenge day 14.
IRV vaccination modulated serum cytokine response to post virulent
HRV challenge
We further examined sera for 7 circulating cytokines in response to vaccination and oral chal-
lenge (Fig 4). No elevated levels of serum cytokines were detected in piglets at 0, 10, 21 and 28
days post vaccination. After oral challenge, we detected elevated levels of IFN-α in sera of
Fig 2. Avidity of rotavirus-specific IgG antibody in sera of control, ID or IM IRV-vaccinated piglets. Shown
are IgG end-titer avidity index percentages (etAI%). Data are presented as mean + one standard error (error bar).
Filled, checker board and open bars represent control, ID and IM groups, respectively.
doi:10.1371/journal.pone.0166038.g002
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Fig 3. Neutralizing activity in sera of control, ID or IM IRV-vaccinated piglets. The neutralizing antibody
titers to Wa (A), WI61 (B) and MW333 (C) strains were determined by neutralization assay. Each serum
specimen was tested at an initial dilution of 1:20. For negative samples at 1:20 dilution, an arbitrary value 10
was used for calculation and graphic illustration. Data are presented as geometric mean titer (GMT) + one
standard error (error bar). Filled, checker board and open bars represent control, ID and IM groups,
respectively. Significant differences are indicated.
doi:10.1371/journal.pone.0166038.g003
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control piglets at day 3 (p< 0.001), which coincidedwith higher fecal RV antigen shedding
and diarrhea scores, but little elevation in sera of ID IRV or IM IRV piglets. Piglets in control
group had a peak level of IL-8 three days post oral challenge, whereas piglets in ID IRV and IM
IRV groups showed delayed IL-8 peak at day 5 following oral challenge.
ID- and IM-administered IRV reduced fecal RV antigen shedding and
diarrhea severity post-challenge
We evaluated the protection of ID- or IM-administered IRV against RV infection in Gn piglets
challenged with VirWa RV by comparing RV antigen shedding in rectal swab samples
Fig 4. Kinetic profiles of cytokines in sera of control, ID or IM IRV-vaccinated piglets. Levels of IL-8 (A) and
IFN-α (B) were measured with Swine Cytokine Magnetic 7-Plex Panel kit as described in the text. Levels of five
other cytokines (IL-1β, IL-4, IL-10, IFN-U, TNF-α) were not elevated (data not shown). Each data point denotes
geometric mean concentration ± one standard error (error bar). Significant differences are indicated.
doi:10.1371/journal.pone.0166038.g004
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(Table 1). All 3 piglets in the control group shed RV antigen with relative high OD values for a
mean duration of 5.3 days. By contrast, only 1 of the 4 piglets in ID IRV group shed rotavirus
antigen in reduced amount and with a mean duration of 0.75 day and a mean cumulative OD
of 0.19, indicating a 91% decrease in antigen shedding. Similarly, only one animal in IM IRV
group shed rotavirus antigen with a mean duration of 0.5 day and a mean cumulative OD of
0.07, indicating a 97% reduction in rotavirus shedding in this group.
We also evaluated the protection of ID- or IM-administered IRV against RV diarrhea inWa
RV-challenged Gn piglets by comparing diarrhea scores in vaccinated animals and placebo
controls (Table 1). Two of the three piglets in control group had diarrhea score of 2 for a mean
duration of 1.3 days and with a mean cumulative score of 2.7. By contrast, all 4 piglets in ID
IRV group had scores1, showing 100% decrease in diarrhea cumulative score as a group and
complete protection against diarrhea. Two of the 4 piglets in IM IRV group had a score of 2 for
only one day (post challenge day 1 or 2), while the other two had scores1 for all 10 days,
showing 63% reduction in diarrhea cumulative score as a group and at least partial protection
against diarrhea.
Discussion
We previously reported enhanced immunogenicity and apparent dose sparing of IRV coated
on a microneedle patch when compared with IM-administered IRV without an adjuvant in
mice. In this study we further evaluated the immunogenicity and protective efficacy of ID-
administered IRV without adjuvant using a hollow microneedle compared with IM-adminis-
tered IRV formulated with Al(OH)3 adjuvant. We demonstrated that both ID- and IM-admin-
istered IRV induced comparable IgA, IgG, IgG antibody avidity and neutralizing antibody
responses, and conferred complete or at least partial protection against homologous rotavirus
infection (challenge) and diarrhea in piglets. Of particular interest was the detection of high
titers of IgA in sera of both ID and IM IRV-vaccinated animals, an observation that challenges
the dogma that parenteral vaccination may not induce IgA response [39–41]. Whether serum
IgA was transferred to the gut and together with serum IgG, mediated protection against rota-
virus infection and diarrhea requires further investigations. Systemic routes of vaccination
Table 1. RV antigen shedding and diarrhea in Gn piglets post-challenge with VirHRV Wa.























Control 3 3/3 (100%) 5.3 2.05 - 2/3 (66%) 1.3 2.7 -
ID 4 1/4 (25%) 0.75 0.19 91% 0/4 (0%) 0 0 100%
IM 4 1/4 (25%) 0.5 0.07 97% 2/4 (50%) 0.5 1 63%
P-value d - 0.143 0.026 <0.001 0.143 0.068 0.078
P-value e 0.143 0.016 <0.001 1.000 0.415 0.445
Gn piglets were vaccinated with control, ID and IM IRV and orally challenged with VirHRV Wa as described in the text. N = number of animals per group.
a Determined by Premiere™ Rotaclone®.
b Diarrhea duration was defined as the number of days with fecal score2. Stool consistency was scored daily (0 = normal; 1 = pasty; 2 = semi-liquid
[moderate diarrhea]; 3 = liquid [severe diarrhea]).
c Mean cumulative score was ∑ (faecal scores2)/number of animals.
d Control vs ID.
e Control vs IM.
doi:10.1371/journal.pone.0166038.t001
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under some circumstances (antigen, adjuvant, and delivery vehicle) have the potential to
induce immune responses in the systemic system and multiple mucosal compartments [42].
The findings in the present study agree with our previous report that IM-administered IRV
was effective in inducing protective immunity against rotavirus infection in piglets [22]. Our
results further showed that a parenterally administered IRV was effective against rotavirus
diarrhea as well. However, two major differencesmerit comments here. We vaccinated animals
with 5 μg antigen formulated with Al(OH)3 in the present study compared with 50 μg antigen
formulated with Al(PO)4 in the prior study. These results indicate that Al(OH)3 or Al(PO)4 are
effective adjuvants for IRV or even an IRV-containing combination vaccine. The observation
that a 1/10 of the previously tested high-dose antigen was as effective in inducing protective
immunity is promising for a low cost vaccine.
The skin is a dynamic organ that harbors elements of the innate and the adaptive immune
systems. Skin is particularly rich in dendritic cells (Langerhans cells) in the epidermis which,
when activated by infection, can mount a robust immune response. Skin immunization has
been demonstrated to be effective against rabies, tuberculosis and other infectious diseases,
including successful eradication of smallpox. However, those ID vaccines were delivered using
old devices (i.e., bifurcated needle) and the Mantoux technique (regular needle and syringe)
which were technically difficult and thus required highly trained personnel and can also be
quite painful [43, 44]. The MicronJet6001 device used in this study was designed to be user
friendly and requires minimum training. In a study that compared trivalent influenza vaccine
(TIV) administered ID or IM in adults aged 65 years showed that ID administration was
associated with decreased pain at the site of injection (P< 0.01) compared to the IM groups
[45].
Interestingly in our study, IFN-α, which is an innate anti-viral cytokine, was not associated
with protection but showed association with HRV replication as indicated by higher fecal shed-
ding OD post challenge in the control group. Our findings line up with the observation in chil-
dren, where vomiting episodes and RV diarrhea significantly correlated with IFN-α levels [46].
In animal studies, IFN-α administered before RV infections reduced RV diarrhea in pigs and
calves [47, 48]. However, pretreatment with IFN-α in neonatal mice had no effect on virus
shedding, suggesting species specific effects [49], and the role of IFN-α in RV clearance in mice
may differ between homologous and heterologous RV infections [50]. In addition, chemokine
IL-8 response was delayed by a few days in IRV-vaccinated piglets compared to controls, the
significance of this finding is not clear.
The present study is subject to several implications and limitations. We simultaneously
compare ID and IM routes for administering IRV. Our findings demonstrated that both ID
IRV and IM IRV induced robust IgA response in sera of piglets suggesting that serum IgA anti-
bodiesmay serve as a proxy to assess the immunogenicity of IRV in clinical trials, similar to
the approach used for the development and licensure of oral rotavirus vaccines. Because of vol-
ume restriction, we chose two sites to administer the vaccine. For IRV vaccination in humans,
we would anticipate a single application site similar to ID-administered concentrated Fluzone
vaccine (Intanza1). The piglets were orally inoculatedwith a virulent human RV Wa G1P[8]
at a dose of 5x105 ID50, the identical dose reported in our previous study [22]. However,
because of the cost and the size of piglets in each litter, we were not able to conduct dosing
experiments to determine whether a further lower dose of IRV would be as effective to induce
protection. In addition, we had to use small numbers of animals in each group. Nevertheless,
the findings of this proof of concept study demonstrate the safety and protective efficacy of
IRV via IM or ID administration in a large animal model. These safety and efficacy data in pre-
clinical studies should help encourage clinical development of a standalone IM or ID IRV first
and subsequently an IRV-containing combination vaccine suitable for use in infants. A safe
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and efficacious IRV combination vaccine has great potential to be implemented globally as it
does not need a separate cold chain and thus simplifies administration, and particularly in
developing countries where RV mortality is high and current oral vaccines seem less
efficacious.
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